中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (9): 665-670.doi: 10.19401/j.cnki.1007-3639.2018.09.004

• 论著 • 上一篇    下一篇

ADIPOQ基因多态性与前列腺癌易感性的相关性研究

顾成元,吴俊龙,朱 煜,许 华,秦晓健,朱 耀,戴 波,叶定伟   

  1. 复旦大学附属肿瘤医院泌尿外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2018-09-30 发布日期:2018-10-26
  • 通信作者: 叶定伟 E-mail:dwye@shca.org.cn
  • 基金资助:
    国家自然科学基金项目(81702537)。

Genetic variations of the ADIPOQ gene and risk of prostate cancer

GU Chengyuan, WU Junlong, ZHU Yu, XU Hua, QIN Xiaojian, ZHU Yao, DAI Bo, YE Dingwei   

  1. Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2018-09-30 Online:2018-10-26
  • Contact: YE Dingwei E-mail: dwye@shca.org.cn

摘要: 背景与目的:环境因素在前列腺癌发病机制中的作用,尤其是高脂肪摄入饮食、缺乏体力活动等引起的肥胖逐渐受到重视。脂联素可能是前列腺癌与肥胖之间潜在的分子递质,本研究旨在探讨编码脂联素的ADIPOQ基因多态性与中国人群前列腺癌发病风险的关联性。方法:提取917例前列腺癌患者和1 036例正常对照男性的外周血DNA,通过TaqMan探针技术检测ADIPOQ基因rs266729和rs182052的多态性。采用Logistic回归模型分析各基因型与前列腺癌发病风险的关系,在此基础上分析其与体质量指数的关系。结果:对照组中rs266729和rs182052两位点的基因型频率均符合Hardy-Weinberg平衡(P=0.29和0.83)。rs266729和rs182052两位点各基因型在两组间的分布差异无统计学意义(P=0.88和0.63)。与野生型相比,两位点的杂合型及突变型携带者患病风险差异无统计学意义(OR=0.97,95%CI:0.81~1.16;OR=0.89,95%CI:0.73~1.09)。分层分析显示,在年龄≤69岁的人群中,rs182052 AA基因型携带者的前列腺癌发病风险仅为AG或GG基因型携带者的73%(95%CI:0.54~0.99),差异有统计学意义(P=0.04)。rs182052遗传变异与体质量指数相关(P=0.03)。结论:ADIPOQ基因rs266729和rs182052可能与中国人群前列腺癌总体发病风险无关,rs182052 AA基因型携带者≤69岁时发病风险较低,并且该位点的遗传变异与前列腺癌患者的体质量指数相关。

关键词: ADIPOQ, 基因多态性, 前列腺癌

Abstract: Background and purpose: Mounting evidence, both epidemiologic and mechanistic, for an association between the obesity and prostate cancer, is of public health interest. Many studies have investigated the role of adiponectin as a putative molecular mediator between obesity and prostate cancer. This study investigated association between ADIPOQ single nucleotide polymorphisms (SNPs, rs266729 and rs182052) and risk of prostate cancer in Chinese men. Methods: Peripheral blood DNA was extracted from 917 prostate cancer patients and 1 036 cancer-free controls. Genotyping was performed using the TaqMan method. Associations between the SNPs and risk of prostate cancer were calculated using multivariate logistic regression models. The analysis of variance (ANOVA) was used to assess associations between SNPs and body mass index (BMI). Results: The genotype frequencies of rs266729 and rs182052 among the controls were in agreement with Hardy-Weinberg equilibrium (P=0.29 and 0.83). We did not observe any statistically significant differences in the distribution of genotype frequencies between the two groups for rs266729 and rs182052 (P=0.88 and 0.63). Compared with major homozygotes, no association between heterozygotes or rare homozygotes of these two SNPs and prostate cancer risk was observed (OR=0.97, 95%CI: 0.81-1.16; OR: 0.89, 95%CI: 0.73-1.09). The protective effect of rs182052 AA genotype was evident in subgroups of age ≤ 69. Further ANOVA analyses revealed a significant association between rs182052 and BMI (P=0.03). Conclusion: Our data did not support an association between the ADIPOQ SNPs (rs266729 and rs182052) and risk of prostate cancer. The young age may enhance the protective effect of rs182052 AA genotype. ADIPOQ rs182052 is associated with BMI in prostate cancer patients.

Key words: ADIPOQ, Polymorphism, Prostate cancer